$GALDY

Galderma Group AG/ADR

Galderma is a dermatology company based in Zug, Switzerland, serving markets worldwide. Its business spans aesthetic injectables, skincare and dermatological treatments. Its brands include Dysport, Restylane, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Differin, AKLIEF, Oracea, NEMLUVIO, Benzac and Loceryl.

No enriched coverage for $GALDY in the last 7 days.

No SEC Form 4 filings for $GALDY in the last 30 days.

See all $GALDY insider activity →
Med

Galderma Expands Relfydess Reach With China Approval For Frown Lines

Galderma (GDERF) received China approval for Relfydess, a neuromodulator for frown lines. Supported by clinical data, it's the first ready-to-use liquid in China. The approval expands Galderma's portfolio in a growing market. GDERF stock closed at $220.14, up 10.82%.

Key deals this week: International Paper, IonQ, Bumble, and more

Varonis Systems (VRNS) rose 2.5% after Proofpoint agreed to acquire it for ~$6.3B. International Paper (IP) gained 7.4% on reports of potential bids for its European packaging business. CCC (CCC) will be acquired for ~$6.1B, Galderma (GALDY) will buy ZO Skin Health for $1.5B, and Bumble (BMBL) surged 57% on a $1.3B acquisition deal. IonQ (IONQ) is acquiring Elisity for up to $1.3B, and STERIS (STE) will buy Xodus Medical for $2.1B.

GALDY sentiment & insider activity

Recent GALDY coverage spans regulation, mergers & acquisitions and earnings.

What's driving GALDY

  • Galderma (GDERF) received China approval for Relfydess, a neuromodulator for frown lines. Supported by clinical data, it's the first ready-to-use liquid in China. The approval expands Galderma's portfolio in a growing market. GDERF stock closed at $220.14, up 10.82%.

    rttnews.com · Oct 23, 2026

  • Guidance raise and strong sales likely boost the stock.

    rttnews.com · Oct 22, 2026

  • Strategic acquisition may boost long‑term growth.

    tradingview.com · Oct 17, 2026

  • The deal is expected to be EPS‑neutral but may slightly dilute margins, likely pressuring the stock modestly.

    rttnews.com · Oct 14, 2026

  • Galderma Group (GDERF) said the EU approved Restylane Shaype, a hyaluronic acid injectable for temporary chin augmentation under the EU Medical Device Regulation. The company cited clinical results showing 83% improved structure at 3 months and 66% at 12 months. Galderma noted Restylane Shaype uses NASHA HD and that its stock closed at $228.55, up 3.91%.

    rttnews.com · Aug 11, 2026

AlphAI scores every news story that mentions GALDY with an AI model for sentiment and relevance, and aggregates insider trades from Galderma Group AG/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GALDY

Score

Key deals this week: International Paper, IonQ, Bumble, and more

Varonis Systems (VRNS) rose 2.5% after Proofpoint agreed to acquire it for ~$6.3B. International Paper (IP) gained 7.4% on reports of potential bids for its European packaging business. CCC (CCC) will be acquired for ~$6.1B, Galderma (GALDY) will buy ZO Skin Health for $1.5B, and Bumble (BMBL) surged 57% on a $1.3B acquisition deal. IonQ (IONQ) is acquiring Elisity for up to $1.3B, and STERIS (STE) will buy Xodus Medical for $2.1B.

$GALDYHighAI 9/10

Galderma To Acquire ZO Skin Health For $1.5 Bln

Galderma Group AG (GALD.SW, GALDY) will acquire ZO Skin Health from Blackstone Inc. (BX) for $1.5 billion, expected to close by early 2027. The deal will be funded through cash and bank financing, adding to Galderma's dermatological skincare portfolio. ZO Skin Health reported $330 million in net sales in the year ended June 2026.

$GDERFMedAI 8/10

Galderma Wins EU Nod For Restylane Shaype In Facial Shaping

Galderma Group (GDERF) said the EU approved Restylane Shaype, a hyaluronic acid injectable for temporary chin augmentation under the EU Medical Device Regulation. The company cited clinical results showing 83% improved structure at 3 months and 66% at 12 months. Galderma noted Restylane Shaype uses NASHA HD and that its stock closed at $228.55, up 3.91%.

$GDERFMedAI 8/10

Galderma Provides FDA Progress Update On RelabotulinumtoxinA Submission

Galderma said the U.S. FDA issued a Complete Response Letter for its BLA submission for relabotulinumtoxinA (Relfydess). The FDA cited manufacturing site inspection observations and requests to optimize analytical methods; Galderma said safety/efficacy sections had no deficiencies. Galderma plans corrective actions and continued FDA dialogue. GDERF shares closed at $238.05, up 12.95% Tuesday.

Related tickers